WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206057
Description: Anaxirone is a synthetic triepoxide alkylating agent with potential antineoplastic activity. Anaxirone alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA synthesis. This agent has been shown to exhibit a broad spectrum of antineoplastic activity against experimental tumors, including those resistant to other alkylating agents.
MedKoo Cat#: 206057
Chemical Formula: C11H15N3O5
Exact Mass: 269.10117
Molecular Weight: 269.2539
Elemental Analysis: C, 49.07; H, 5.62; N, 15.61; O, 29.71
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Anaxirone; triglycidylurazol; Abbreviation: TGU; Chemical structure: 124triglycidylurazol.
IUPAC/Chemical Name: 1,2,4-tris(oxiran-2-ylmethyl)-1,2,4-triazolidine-3,5-dione
InChi Key: ZTXDHEQQZVFGPK-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H15N3O5/c15-10-12(1-7-4-17-7)11(16)14(3-9-6-19-9)13(10)2-8-5-18-8/h7-9H,1-6H2
SMILES Code: O=C(N1CC2OC2)N(CC3OC3)N(CC4OC4)C1=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 269.2539 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Holdener EE, Clavel M, Sessa C, ten Bokkel Huinink W, Siegenthaler P, Ludwig C, Klepp O, Renard G, Decoster G, Pinedo HM. Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study. Eur J Cancer. 1994;30A(3):394-5. PubMed PMID: 8204365.
2: George M, Scotto V, Carnino F, Dodion P, ten Bokkel Huinink WW, Rotmensz N, Vermorken JB. Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study. Eur J Cancer Clin Oncol. 1987 Jun;23(6):867-9. PubMed PMID: 3653204.
3: Fiebig HH, Henss H, Arnold H, von BÃ¼ltzingslÃ¶wen F, Klee M, Queisser W, Peukert M. Phase II trial of anaxirone in advanced non-small cell lung cancer. Cancer Treat Rep. 1987 May;71(5):539-40. PubMed PMID: 3567979.
4: Schilcher RB, Young JD, Nowrousian MR, Hoffmann B, Schmidt CG. Reversed-phase high-performance liquid chromatographic determination of anaxirone in biological specimens. J Chromatogr. 1986 May 28;378(1):248-53. PubMed PMID: 3733978.
5: Hilgard P, Peukert M, Pohl J. alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent. Cancer Treat Rev. 1984 Jun;11(2):115-20. PubMed PMID: 6498858.